Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.

about

Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.

Item

http://www.wikidata.org/entity/Q53538428

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.

@en

Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.

@nl

type

Item

label

Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.

@en

Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.

@nl

prefLabel

Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.

@en

Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.

@nl

P1476

Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.

@en

P2093

Steven E Vogl

http://www.w3.org/2001/XMLSchema#string

P2860

Premature menopause or early menopause: long-term health consequences

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.

Regional Nodal Irradiation in Early-Stage Breast Cancer.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

P2888

s10549-017-4379-1

P304

1-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1007/S10549-017-4379-1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

166

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28695299

http://www.w3.org/2001/XMLSchema#string